Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.
Bioventus Inc. (Nasdaq: BVS) is a medical technology company that describes itself as a global leader in innovations for active healing. The Bioventus news stream features company announcements, financial updates and product milestones that reflect its focus on Pain Treatments, Surgical Solutions and Restorative Therapies.
Investors following BVS news will find regular earnings releases where Bioventus reports net sales, segment performance across Pain Treatments, Surgical Solutions and Restorative Therapies, and metrics such as net income, Adjusted EBITDA and non-GAAP earnings. These updates often include commentary on organic revenue trends, portfolio changes like the divestiture of the Advanced Rehabilitation Business, and the impact of factors such as foreign currency and tariffs.
The company also issues product and regulatory news, including announcements of U.S. Food and Drug Administration (FDA) 510(k) clearances. Recent examples include clearances for TalisMann and StimTrial, two Peripheral Nerve Stimulation products for chronic pain management that Bioventus highlights as expanding its non-opioid, minimally invasive therapy portfolio.
Bioventus news items cover capital structure and financing developments, such as the entry into a new senior secured credit agreement that refinanced prior debt, increased revolving capacity and reduced interest margins. In addition, the company regularly announces participation in major healthcare and investor conferences hosted by firms such as J.P. Morgan, Piper Sandler, Morgan Stanley and Canaccord Genuity.
For readers tracking BVS, the news page provides a centralized view of Bioventus’ financial performance, product pipeline progress, regulatory milestones and corporate events, helping contextualize how its Pain Treatments, Surgical Solutions and Restorative Therapies businesses evolve over time.
Bioventus (Nasdaq: BVS) has appointed Mary Kay Ladone to its Board of Directors, effective July 15, 2021. Ladone, a seasoned executive with over 30 years in global healthcare, will also serve on the Audit and Risk Committee and the Compensation Committee. CEO Ken Reali noted her expertise in strategic planning and investor relations, which will aid Bioventus in its growth strategy focused on new product development and M&A. Ladone previously held positions at Hillrom Holdings and Baxalta, enhancing her credentials in corporate development and investor relations.
Bioventus (BVS) has launched OSTEOAMP SELECT Flowable, an innovative allograft bone graft substitute aimed at enhancing surgical outcomes in spine fusion and other procedures. This product is 100% allograft, free from synthetic carriers, and is designed for smooth handling and effective retention at the grafting site. Available in three sizes, the flowable allograft is terminally sterilized and processed to meet stringent tissue banking standards. The launch follows a limited release in select markets earlier this year, with enthusiastic endorsements from leading spine surgeons highlighting its utility in minimally invasive surgeries.
Bioventus (Nasdaq: BVS) announced a minority investment in Vaporox, a company specializing in diabetic foot ulcer (DFU) wound healing therapy. Vaporox's patented Vaporous Hyperoxia Therapy™ has achieved an 85% healing rate for DFUs typically unresponsive to standard care. This investment aims to serve as a stepping stone to a potential acquisition, enhancing Bioventus's portfolio in the growing DFU treatment market. The terms of the investment remain undisclosed, but it is noted as non-material to Bioventus's finances.
Bioventus (BVS) announced it will release its fiscal Q2 2021 results after market close on August 10, 2021. Management will conduct a conference call at 5:00 PM ET the same day to discuss these results and provide a business update. Interested parties can join the call by dialing the provided numbers. A webcast will also be available on the company’s investor relations website, which will be archived for replay until August 10, 2022. The company focuses on delivering clinically proven products for active healing.
Bioventus Inc. (Nasdaq: BVS) announced that its human placental tissue product, PTP-001, significantly reduced pain and cartilage degeneration in a rat osteoarthritis model during a six-week study. Findings published in Osteoarthritis and Cartilage revealed that PTP-001's efficacy matched corticosteroid treatment. The company sees PTP-001 as a promising candidate for managing osteoarthritis symptoms and potentially modifying the disease. Further research and development plans are in place for PTP-001, aimed at addressing unmet clinical needs.
Bioventus (Nasdaq: BVS) announced its participation in two upcoming virtual conferences: the Canaccord Genuity Virtual Musculoskeletal Conference on May 20 at 8:30 a.m. ET and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9 at 11:20 a.m. ET. Presentation materials will be accessible on the investor relations section of the Bioventus website prior to each event. A live audio webcast and replay links will also be available for 30 days afterward. Bioventus focuses on innovations for active healing, particularly in osteoarthritis and various pain management solutions.
Bioventus Inc. (Nasdaq: BVS) reported its financial results for Q1 2021, revealing net sales of $81.8 million, a 4.0% year-over-year increase. Net income soared to $24.5 million, up 133.9% from last year. However, Adjusted EBITDA fell to $11.1 million, a decline of 22.3%. The company completed its acquisition of Bioness, enhancing its market reach in the neuromodulation sector. Bioventus raised its 2021 revenue guidance by $4 million to a new range of $406 million, anticipating a year-over-year increase of 23% to 26%.
Bioventus Inc. (Nasdaq: BVS) announced the commercial launch of the Bioness Integrated Therapy System (BITS) for Balance, marking significant advancements in rehabilitation technology. The system includes over 40 new programs, enhancing the platform's ability to assist healthcare providers in assessing and tracking patients' balance and strength. This initiative aligns with the increasing global need for rehabilitation services, as highlighted by recent studies indicating a substantial portion of the population could benefit from such therapies.
Bioventus (BVS) announced that it will release its first quarter fiscal year 2021 financial results after market close on May 12, 2021. A conference call to discuss the results will follow at 5:00 p.m. ET on the same day. Shareholders and interested parties can participate by dialing 844-945-2085 or accessing the live webcast via the company's investor relations website. Bioventus continues to focus on providing innovative and clinically proven solutions for active healing, including recent expansions through the acquisition of Bioness, enhancing its product portfolio for pain management and rehabilitation.
Bioventus (Nasdaq: BVS) has acquired Bioness for $45 million upfront, with potential additional payments up to $65 million based on performance milestones. Bioness, known for its neuromodulation and rehabilitation technologies, will enhance Bioventus’ portfolio and is expected to contribute positively to revenue and net income post-acquisition. The move aligns with Bioventus' strategy to leverage its existing infrastructure for growth, targeting a market worth over $8 billion. In 2020, Bioness reported $40 million in revenue.